key: cord-0950902-xj6n5z9y authors: Xie, Weijia; Wu, Na; Wang, Bin; Xu, Yu; Zhang, Yao; Xiang, Ying; Zhang, Wenjing; Chen, Zheng; Yuan, Zhiquan; Li, Chengying; Jia, Xiaoyue; Shan, Yifan; Xu, Bin; Bai, Li; Zhong, Li; Li, Yafei title: Fasting plasma glucose and glucose fluctuation are associated with COVID-19 prognosis regardless of pre-existing diabetes date: 2021-09-06 journal: Diabetes Res Clin Pract DOI: 10.1016/j.diabres.2021.109041 sha: 495813d01e8a8fc7d5e1dbacfdcd8cb91764a56c doc_id: 950902 cord_uid: xj6n5z9y Aims We aimed to investigate the role of Fasting Plasma Glucose (FPG) and glucose fluctuation in the prognosis of COVID-19 patients stratified by pre-existing diabetes. Methods The associations of FPG and glucose fluctuation indexes with prognosis of COVID-19 in 2,642 patients were investigated by multivariate Cox regression analysis. The primary outcome was in-hospital mortality; the secondary outcome was disease progression. The longitudinal changes of FPG over time were analyzed by the latent growth curve model in COVID-19 patients stratified by diabetes and severity of COVID-19. Results We found FPG as an independent prognostic factor of overall survival after adjustment for age, sex, diabetes and severity of COVID-19 at admission (HR: 1.15, 95% CI: 1.06-1.25, P=1.02×10-3). Multivariate logistic regression analysis indicated that the standard deviation of blood glucose (SDBG) and largest amplitude of glycemic excursions (LAGE) were also independent risk factors of COVID-19 progression (P=0.03 and 0.04, respectively). The growth trajectory of FPG over the first 3 days of hospitalization was steeper in patients with critical COVID-19 in comparison to moderate patients. Conclusions Hyperglycemia and glucose fluctuation were adverse prognostic factors of COVID-19 regardless of pre-existing diabetes. This stresses the importance of glycemic control in addition to other therapeutic management. Among various comorbidities of COVID-19, diabetes has been reported as the 68 second most common comorbidity after hypertension [1] . The overall proportion 69 of diabetes in COVID-19 patients ranges from 5.3% to 20% in Chinese studies 70 [2] [3] [4] [5] [6] . In a more recent study in Italy, the diabetes prevalence was 17% among 71 COVID-19 patients admitted to intensive care units (ICUs) [7] . In the USA, the 72 COVID-19-Associated Hospitalization Surveillance Network (COVID-NET) 73 reported a diabetes prevalence of 28.3% in hospitalized adult patients [8] . 74 Diabetes was associated with higher mortality in COVID-19: the largest 75 epidemiological investigation in China indicated that the mortality of with diabetes (up to 7.3%) is much higher than that of the patients without any 77 comorbidities (0.9%) [9] . Pre-existing diabetes has been reported as a risk 78 factor to influence the progression and prognosis of COVID- 19 [10] . 79 As a metabolic syndrome, the pathogenicity of diabetes involves a chronic, low-80 grade inflammatory response characterized by compromised innate immune 81 response and elevated level of inflammatory factors, which might exacerbate 82 the inflammatory storm of 12] . On the other hand, viral infections 83 have been known to cause sharp fluctuation of blood glucose level [13] , which 84 in turn can induce oxidative stress and inflammation in patients with diabetes 85 [14] [15] [16] , and damage the blood vessel endothelium [17] , hence creating a 86 vicious circle after a viral infection. 87 Nevertheless, most studies investigating the independency of diabetes-related 88 phenotypes as risk factors of COVID-19 progression led to conflicting 89 conclusions [10, [18] [19] [20] . The CORONADO study found that HbA1c was not 90 significantly associated with the primary outcomes of COVID-19 (i.e., 91 mechanical ventilation and/or death within 7 days). Their finding suggested that 92 long-term glucose control in diabetes patients has no effect on prognosis. However, they also found that admission plasma glucose was 94 significantly associated with the primary outcome [21] . In-hospital 95 hyperglycemia has been associated with worse COVID-19 prognosis in several 96 previous studies [22] [23] [24] [25] . In addition, treating hyperglycemic patients with 97 insulin infusion had led to a lower risk of severe disease regardless of prior 98 diabetes history. Although the sample size (n=59) of this study was limited and 99 only COVID-19 patients with moderate disease were included [26] . 109 This was a retrospective study of patients with SARS-Cov-2 infection who were 110 admitted to Huoshenshan hospital from February 1, 2020 to March 24, 2020. 111 Huoshenshan hospital (in Wuhan, China) was an emergency specialty field 112 hospital designated for treating Categorical variables were expressed as frequency rates and percentages (%). Continuous variables were expressed as median and the interquartile range 182 (IQR). If the data were in normal distribution, t-test was used in comparison of 183 two groups. If the data were non-normal distribution data, Mann-Whitney U test 184 was used in comparison between two groups. Categorical variables between 185 groups were compared using the Chi-square test or Fisher exact test. The multivariable-adjusted model was used, including age, sex, diabetes, and 192 the severity of COVID-19 disease at admission to hospital. Table 1 : the median age was 61 years (IQR, 50-68) 219 and 1264 (50.50%) were female. The proportion of patients with smoking 220 (7.03%) or drinking behaviors (4.08%) were both lower than that of the general of COVID-19 patients were taking oral medication for blood glucose control, the 225 proportion was higher for both hypoglycemic (23.53%) and hyperglycemic 226 (51.50%) groups. At admission to hospital, 0.91% of the patients were classified 227 as "mild" in terms of the spectrum of severity of COVID-19, 68.64% as 228 "moderate", 29.07% as "severe", 1.38% as critical ( Table 1) . Table 2) . We found that diabetes was not a significant 235 risk factor for OS (HR diabetes : 1.13, 95% CI 0.57-2.25, P =0.74) ( Table 2) . 236 However, FPG was a significant risk factor for OS (HR FPG : 1.12, 95% CI 1.05-237 1.20, P =1.33×10 -3 ) (Table S1) , and remained to be significant after further 238 adjustment for pre-existing diabetes (HR FPG : 1.15, 95% CI 1.06-1.25, P 239 =1.02×10 -3 ) ( Table S1 ). Given that in our data approximately 70% of COVID-240 19 patients with diabetes were taking oral medication for blood glucose control 241 before and during hospital stay, we additionally adjusted this variable and the 242 results remained to be significant (HR FPG : 1.19, 95% CI 1.09-1.30, P =7.51×10 -243 5 ) ( Table S2) . 244 Next, we investigated the influence of diabetes and FPG on disease (Table S1) , whereas FPG showed 249 significant associations (OR FPG : 1.25, 95% CI 1.16-1.35, P =9.13×10 -9 ) ( Table 250 S1 ) and remained to be significant after further adjustment for oral medication 251 of blood glucose control (OR FPG : 1.27, 95% CI 1.17-1.37, P =3.33×10 -9 ) ( Table 252 S2). As shown in Table 1 , we divided patients into three groups according to their 256 FPG levels at admission: hypoglycemic (FPG < 3.3 mmol/L), normoglycemic 257 (3.3 mmol/L ≤ FPG < 7.8 mmol/L) and hyperglycemia (FPG ≥ 7.8 mmol/L). We 258 observed that both hypoglycemic and hyperglycemic COVID-19 patients had 259 higher death rate and progression rate in comparison to that of the overall group. In these 101 patients, 67.33% were with previously diagnosed diabetes, among 317 which 34.67% were with diabetes but without any other comorbidities. None of 318 the patients with BGM data was in the mild spectrum of COVID-19, 65% was 319 classified in moderate type, 33% in severe type, and 2% in critical type. severe COVID-19 regardless of pre-existing diabetes. 379 We used the latent growth curve model to analyze the longitudinal change of 380 FPG over time in COVID-19 patients after admission to hospital. We included 381 625 patients whose FPG levels have been measured on three consecutive days 382 from Day 1 of hospital admission. First, we used diabetes as a predictor for the variations in intercept and slope 384 of the change of FPG (Figure 3 A) . The regression intercept predicted by 385 diabetes was 3.263 (Table S3) , which indicated that the initial status of FPG in 386 COVID-19 patients with diabetes was 3.263 mmol/L higher in comparison to 387 patients without diabetes on Day1 of hospital stay. The slope predicted by 388 diabetes is negative (-0.189) but the P-value of the variations in slopes was 389 insignificant (P slope =0.139) (Table S3) , which suggested there was no 390 significant difference in terms of FPG changes over time for patients with 391 diabetes and without diabetes (Figure 3 A) . 392 Then we used the severity of COVID-19 at admission as a predictor for the 393 variations in intercept and slope of the change of FPG (Figure 3 B) . The slope 394 predicted by the severity of COVID-19 was positive (0.296) with a significant P-395 value (P slope = 0.001) ( Table S3) , which suggested that the growth trajectory of 396 FPG for severe patients was steeper than that of moderate patients. In other 397 words, the positive gains of FPG over time for severe patients was significantly 398 more than the positive gains over time for moderate patients. 399 We then applied a combined model with two regressors (i.e., diabetes and (Table S3) . 403 Because CRP, creatine kinase, D-dimer and interleukin-6 (IL-6) were the 4 404 inflammatory biomarkers significantly associated with glucose fluctuation 405 indexes (Table 3) , we also applied these 4 inflammatory biomarkers as 406 predictors for the variations in intercept and slope of the change of FPG ( Figure 407 S3) (Table S4) . For patients whose baseline levels of IL-6 or D-dimer were 408 beyond the normal range at admission, the positive gain of FPG over time was 409 significantly more than that in patients whose baseline levels of IL-6 or D-dimer 410 were within normal range (Figure S3 A & B) . However, no significant difference 411 in FPG slopes was observed for CRP and creatine kinase (Figure S3 C & D) . 412 Cox regression analysis showed that 3-day change of FPG was associated with 413 worse prognosis after adjustment of the baseline IL-6 and D-dimer (Table S5) . Our findings agreed with a couple of previous studies that, in multivariate 416 analysis after adjustment for age and sex, diabetes was not an independent 417 risk factor for in-hospital death of 32, 33] . Moreover, our 418 findings extended the previous work by showing that abnormal glycemic profile 419 was an independent risk factors of COVID-19 survival regardless of the pre-420 existing diabetes status. In addition, the growth trajectory of FPG over the first 421 3 days of hospital stay was steeper in patients with more severe 422 whereas there was no significant difference in the growth trajectories of FPG in 423 patients with and without pre-existing diabetes. This is generally in keeping with 424 the findings of hyperglycemia was associated with worse clinical outcomes (i.e., higher 426 demand for oxygen support or positive-pressure ventilation), and higher 427 glycemic variability was observed in patients with acute COVID-19 as 428 compared to healthy controls. Notably, they reported that glycemic abnormality 429 persisted in some patients who recovered from COVID- 19 [23] . 430 We observed J-shaped associations between FPG and COVID-19 mortality 431 and disease progression, with lowest mortality within the range of normal blood 432 sugar levels (4.0 to 5.4 mmol/L) (Figure 1) . The influence of hyperglycemia on 433 adverse outcomes of COVID-19 were generally stronger in patients without 434 diabetes than in patients with diabetes (Figure 2 A & B) , indicating importance 435 of blood glucose monitoring in COVID-19 patients without pre-existing diabetes. 436 We also observed that the risk conferred by hyperglycemia became (Table 3 & Figure S2 ). It was also worth pointing out that our study suffered from the intrinsic limitation Our study also showed that elevated FPG levels in the first 467 3 days after admission was associated with a higher risk of death and disease 468 progression even after adjustment of baseline IL-6 and D-dimer levels ( Table 469 S5 ). Unfortunately, IL-6 and D-dimer measurements were not taken as 470 frequently as FPG in our data, so we cannot examine how the inflammatory 471 biomarkers changed along with blood glucose levels. [40]. Whilst both type 1 and type 2 diabetes are characterized by having higher 499 than normal blood glucose levels, their pathophysiology is fundamentally 500 different. Reassuringly, a preliminary study suggested that there was no 501 increase of risk for people with type 1 diabetes hospitalized for COVID -19 [21] . In future studies, it is important to distinguish COVID-19 patients with type1 and 503 type 2 diabetes and investigate whether they have different complications and 504 prognosis of Abnormal glycemic status is an independent risk factor for poor prognosis of Clinical course and outcomes of critically ill patients with SARS-561 CoV-2 pneumonia in Wuhan, China: a single-centered, retrospective, observational study Novel Coronavirus (2019-nCoV) Pneumonia Clinical features of patients infected with 2019 novel 566 coronavirus in Wuhan Clinical characteristics of 140 patients infected with SARS-568 CoV-2 in Wuhan Epidemiological and clinical characteristics of 99 cases of 570 2019 novel coronavirus pneumonia in Wuhan, China: a descriptive study Clinical Characteristics of 138 Hospitalized Patients With Novel Coronavirus-Infected Pneumonia in Wuhan, China Baseline Characteristics and Outcomes of 1591 Patients Infected With SARS-CoV-2 Admitted to ICUs of the Lombardy Region Hospitalization Rates and Characteristics of Patients 578 Hospitalized with Laboratory-Confirmed Coronavirus Disease 2019 -COVID-NET, 14 States MMWR Morb Mortal Wkly Rep Timely blood glucose management for the outbreak of 2019 581 novel coronavirus disease (COVID-19) is urgently needed Diabetes is a risk factor for the progression and prognosis of 584 COVID-19 COVID-19 and Diabetes: A Collision and 586 Collusion of Two Diseases Why is hyperglycaemia worsening COVID-19 and 588 its prognosis? Glycemic Variability in Diabetes Increases the 590 Severity of Influenza Acute and chronic fluctuations in blood glucose levels 592 can increase oxidative stress in type 2 diabetes mellitus The complex combination of COVID-19 and 595 diabetes: pleiotropic changes in glucose metabolism Can COVID-19 cause diabetes? Nat Metab Intermittent high glucose enhances apoptosis related 598 to oxidative stress in human umbilical vein endothelial cells: the role of protein kinase C and 599 NAD(P)H-oxidase activation Clinical Characteristics and Risk Factors for Mortality of COVID-601 Patients With Diabetes in Wuhan, China: A Two-Center, Retrospective Study COVID-19 in People With Diabetes: Urgently Needed 604 Association of Blood Glucose Control and Outcomes in 606 Patients with COVID-19 and Pre-existing Type 2 Diabetes Phenotypic characteristics and prognosis of inpatients 609 with COVID-19 and diabetes: the CORONADO study Acute and long-term disruption of 613 glycometabolic control after SARS-CoV-2 infection Glycemic Characteristics and Clinical Outcomes of COVID-615 Patients Hospitalized in the United States Glycemic control before admission is an important determinant 617 of prognosis in patients with coronavirus disease 2019 Outcomes in Patients With Hyperglycemia 620 Affected by COVID-19: Can We Do More on Glycemic Control? Diabetes Care Management of hyperglycemia in 623 hospitalized patients in non-critical care setting: an endocrine society clinical practice 624 guideline Diabetes Association consensus statement on inpatient 627 glycemic control. Diabetes Care Tobacco and the lung cancer epidemic in China Analysis of the alcohol drinking behavior and influencing 631 factors among emerging adults and young adults: a cross-sectional study in Wuhan, China. 632 BMC Public Health Experts Consensus on Management of Glycemic Variability of Diabetes Mellitus Epidemiology, clinical course, and outcomes 636 of critically ill adults with COVID-19 in New York City: a prospective cohort study Cardiometabolic multimorbidity is associated 639 with a worse Covid-19 prognosis than individual cardiometabolic risk factors: a multicentre 640 retrospective study (CoViDiab II) Newly diagnosed diabetes is associated with a higher risk of 642 mortality than known diabetes in hospitalized patients with COVID-19 Type 2 diabetes as an inflammatory disease Practical recommendations for the management of Hypoglycemic group compared to normoglycemic group (the 729 reference) in chi2 test when n>5 (Fisher's exact when n 5) Hyperglycemic group compared to normoglycemic group (the 731 reference) in chi2 test when n>5 (Fisher's exact when n 5) Hypoglycemic group compared to normoglycemic group (the 733 reference) in Two-sample Wilcoxon rank-sum Hyperglycemic group compared to normoglycemic group (the 735 reference) in Two-sample Wilcoxon rank-sum other comorbidity) * : COVID-19 patients with pre-existing 737 diabetes but without any of the following common comorbidities: hypertension, 738 coronary heart disease (CHD) The multivariate Cox regression analysis was adjusted for age, sex, and 745 severity of COVID-19 at admission to hospital † To make Hazard Ratios (HR) comparable for all the risk factors, the 747 continuous variables in the laboratory tests were converted into binary 748 variables (i.e. abnormal or normal) using their normal ranges as the cut-offs The values of cut-offs were retrieved from the reference ranges for medical 750 tests used by Huoshenshan hospital (shown in the brackets) DBP, diastolic blood pressure; SBP, systolic 752 blood pressure; CHD, coronary heart disease; CORD, chronic obstructive 753 pulmonary disease; ARDS: acute respiratory distress syndrome; LDH, lactate 754 Dehydrogenase; α-hbdh, α-Hydroxybutyrate dehydrogenase; BNP, B-type 755 natriuretic peptide; CRP, C-reactive protein Abbreviations: FPG, fasting plasma glucose; SDBG, standard deviation of 765 blood glucose; %GV, percentage coefficient of variation for glucose; LAGE: 766 largest amplitude of glycemic excursions; PPGE, postprandial glucose 767 excursions; CRP, C-reactive protein; ALP, Alkaline 768 Phosphatase; α-hbdh,α-Hydroxybutyrate dehydrogenase GGT, gamma-769 glutamyl transferase; LDH Linear regression analysis adjusted for age, sex, diabetes, and the severity of 772 COVID-19 at admission to hospital survival between the three groups were compared using the log-rank test, and  During hospitalization, the increase of FPG over time for severe patients of 720 COVID-19 was significantly more than that for moderate patients, but no 721 significant difference between patients with and without diabetes.